About Neogene Therapeutics
Neogene Therapeutics is a Healthcare company based in New York (United States) founded in 2018 by Carsten Linnemann, and was acquired by Astrazeneca in November 2022. T-cell therapies targeting neo-antigens in cancer cells are developed. Neogene Therapeutics has raised $125 million across 2 funding rounds from investors including Astrazeneca, TPG and Syncona. Its chief executive, as recorded, is Carsten Linnemann. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Neogene Therapeutics was founded in 2018 in New York, United States, within the biotechnology sector focused on oncology. T-cell therapies are developed to treat cancer by targeting mutated proteins known as neo-antigens, which arise from DNA mutations on cancer cells. Operations center on providing these therapies to patients, with a presence in the United States. Leadership includes co-founder and CEO Carsten Linnemann.
- Headquarters New York, United States
- Founders Carsten Linnemann
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website neogene.com
- Social LinkedIn
- Acquired by Astrazeneca (Nov 2022)
- Total Equity Funding$125M (USD)
in 2 rounds
- Latest Funding Round$110M (USD), Series A
Sep 2020
- InvestorsAstrazeneca
& 8 more
- Acquired byAstrazeneca
(Nov 2022)
Funding Insights of Neogene Therapeutics
Neogene Therapeutics has successfully raised a total of $125M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $110 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $125M
- Total Rounds 2
- Last Round Series A — $110M
- First Round $15M
(May 2019)
- Investors Count 8
All 2 funding rounds of Neogene Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $110M | Series A | – | EcoR1, Jeito | |
| May 2019 | $15M | Seed | – | Vida Ventures, TPG | – |
9 investors in total: 9 institutional.
Investors in Neogene Therapeutics
Neogene Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, TPG and Syncona.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Jeito Capital is focused on financing medical innovation globally. | jeito.life | Paris, France | ||
Healthcare investments are managed via private equity by Syncona. | 2012 | synconaltd.com | London, United Kingdom | |
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Pontifax Venture Capital is focused on life sciences investments. | pontifax.com | Herzeliya, Israel | ||
Biomedical innovations are transformed into therapies by Vida Ventures. | vidaventures.com | Boston, United States | ||
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Two River is engaged in building life science companies. | tworiver.com | New York, United States | ||
| ecor1cap.com | ||||
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for Neogene Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neogene Therapeutics
9 people are tracked at Neogene Therapeutics (2 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Carsten Linnemann | Co-Founder & CEO | Leadership |
Sunny Xie | Vp, Biometrics | Leadership |
Wendy De Klerk | Senior Research Associate | Team |
Gavin M. Bendle | SVP, Research & Development | Team |
Barun Gupta | Innovting Cell Therapy Digital Platform | Team |
Sterre Erades | Research Associate | Team |
Nargess K. | Principal Scientist | Team |
Bas van der Holst | Senior Research Associate | Team |
Hendrik F. van Essen | Senior Research Associate | Team |
Complete people profiles for Neogene Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Neogene Therapeutics
4 dated milestones of Neogene Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Neogene Therapeutics is founded.
- Funding First funding round of $15.0M.
- Funding Latest funding round, Series A, of $110.0M.
- Exit Acquired by Astrazeneca.
Competitors of Neogene Therapeutics
Neogene Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Neogene Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Neogene Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neogene Therapeutics
Complete news archive for Neogene Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neogene Therapeutics
Neogene Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Neogene Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Carsten Linnemann is the CEO of Neogene Therapeutics, as recorded in our data. They have also founded this company.
Neogene Therapeutics is a funded company, having raised a total of $125M across 2 funding rounds to date. The company's 1st funding round was a Seed of $15M, raised on May 2019.
Neogene Therapeutics was founded in 2018 in New York, United States, within the biotechnology sector focused on oncology. T-cell therapies are developed to treat cancer by targeting mutated proteins known as neo-antigens, which arise from DNA mutations on cancer cells. Operations center on providing these therapies to patients, with a presence in the United States. Leadership includes co-founder and CEO Carsten Linnemann.
Neogene Therapeutics's top competitors include C4 Therapeutics, Erasca and MiRagen.
Neogene Therapeutics has 9 investors. Key investors include Astrazeneca, TPG, Syncona, EcoR1, and Jeito Capital.
Yes. Neogene Therapeutics was acquired by Astrazeneca in November 2022.